Preclinical and clinical studies highlight the significant benefits of GLP-1 receptor agonists in improving renal outcomes for patients with diabetic kidney disease (DKD), mainly by reducing albuminuria. The gene discussed is GLP1R; the disease is diabetic kidney disease.